Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Neuralstem: Previewing Upcoming Important Events and Some Thoughts on the StemCell Patent Infringement Lawsuit (CUR, $3.62 Buy, August 26, 2014)

Key Points

The phase 2 trial of NSI-566 in 15 ALS patients has completed enrollment (surgeries) and final topline data could…
Read more…

Cytokinetics: More Thoughts on the Potential for a Phase 3 Trial of Tirasemtiv in ALS (CYTK, Buy, $4.20)

Investment Thesis

In listening carefully to Cytokineticsí (CYTK) comments over the last three months, I am convinced that the Company will…
Read more…

Cytokinetics: I Think That the Company May Decide to Do A Phase 3 Trial with Tirasemtiv (CYTK, $4.70, Buy, For Subscribers Only)

Overview on Clinical Status of Tirasemtiv

I believe that Cytokinetics (CYTK) will decide to move tirasemtiv into phase 3 registration trials…
Read more…

Neuralstem: Dr. Eva Feldmanís Latest Presentation on The Use of CURís Stem Cells in ALS (CUR, Buy, $4.04)

Overview
Dr. Eva Feldman is the lead investigator for the clinical trials of Neuralstemís (CUR) NSI-566 spinal cord stem cells in…
Read more…

Neuralstem (CUR, Buy, $4.48) Publishing of Phase 1 Results in Annals of Neurology Causes Price Surge (Paid Subscribers Only)

Introduction

The final results of the phase 1 trial of Neuralstemís (CUR) NSI-566 spinal cord stem cells in the treatment of…
Read more…

Neuralstem: Sizing Up Potential Key Events of 2014 (CUR, $3.42)

Investment Thesis and Overview
Neuralstemís clinical trial programs and accompanying results for its two key drugs, the neural stem cell product…
Read more…

Neuralstem: Evidence Increasingly Suggests its Neural Stem Cells are Effective in ALS (CUR, $2.57)

Thoughts on the Stock Price
I have been recommending Neuralstem†(CUR) since my initiation report†of November 5, 2012 at a price of…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, June 2, 2013

Overview of This Week's Report
This week I published a major report on Alimera Sciences and pSivida which led to my…
Read more…

Neuralstem: Update on Phase I Trial of Neural Stem Cells in ALS is Encouraging (CUR, $1.45)

Purpose of Report
An encouraging update on the phase I trial of Neuralstem's (CUR) neural stem cells in ALS was just…
Read more…